{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:27:19Z","timestamp":1791581239200,"version":"4.3.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11864-022-00954-4","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T03:04:33Z","timestamp":1646622273000},"page":"348-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer"],"prefix":"10.1007","volume":"23","author":[{"given":"Nicole","family":"Bates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosayaba","family":"Osazuwa-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-2863","authenticated-orcid":false,"given":"Jeffrey F.","family":"Scherrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"issue":"5","key":"954_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/0194599818783964","volume":"159","author":"JD Cramer","year":"2018","unstructured":"Cramer JD, Johnson JT, Nilsen ML. Pain in head and neck cancer survivors: prevalence, predictors, and quality-of-life impact. Otolaryngol Head Neck Surg. 2018;159(5):853\u20138.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"954_CR2","doi-asserted-by":"crossref","unstructured":"Osazuwa-Peters N, Polednik KM, Tutlam NT, Tait R, Scherrer J, Barnes JM, et al. Depression, chronic pain, and high-impact chronic pain among cancer survivors. J Clin Oncol. 2021;39.","DOI":"10.1200\/JCO.2021.39.15_suppl.12085"},{"issue":"23","key":"954_CR3","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.1002\/cncr.32450","volume":"125","author":"NN Sanford","year":"2019","unstructured":"Sanford NN, Sher DJ, Butler SS, Xu X, Ahn C, Aizer AA, et al. Prevalence of chronic pain among cancer survivors in the United States, 2010-2017. Cancer. 2019;125(23):4310\u20138.","journal-title":"Cancer."},{"issue":"3","key":"954_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11606-013-2648-1","volume":"29","author":"JF Scherrer","year":"2014","unstructured":"Scherrer JF, Svrakic DM, Freedland KE, Chrusciel T, Balasubramanian S, Bucholz KK, et al. Prescription opioid analgesics increase the risk of depression. J Gen Intern Med. 2014;29(3):491\u20139.","journal-title":"J Gen Intern Med"},{"key":"954_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1370\/afm.1885","volume":"14","author":"JF Scherrer","year":"2016","unstructured":"Scherrer JF, Salas J, Copeland LA, Stock EM, Ahmedani BK, Sullivan M, et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. Ann Fam Med. 2016;14:54\u201362.","journal-title":"Ann Fam Med"},{"issue":"4","key":"954_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jpain.2015.12.012","volume":"17","author":"JF Scherrer","year":"2016","unstructured":"Scherrer JF, Salas J, Copeland LA, Stock EM, Schneider FD, Sullivan M, et al. Increased risk of depression recurrence after initiation of prescription opioids in noncancer pain patients. J Pain. 2016;17(4):473\u201382.","journal-title":"J Pain"},{"key":"954_CR7","doi-asserted-by":"crossref","unstructured":"Wilson L, Bekeris J, Fiasconaro M, Liu J, Poeran J, Kim DH, et al. Risk factors for new-onset depression or anxiety following total joint arthroplasty: the role of chronic opioid use. Reg Anesth Pain Med. 2019.","DOI":"10.1136\/rapm-2019-100785"},{"issue":"2","key":"954_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamapsychiatry.2020.3554","volume":"78","author":"DB Rosoff","year":"2021","unstructured":"Rosoff DB, Smith GD, Lohoff FW. Prescription opioid use and risk for major depressive disorder and anxiety and stress-related disorders: a multivariable Mendelian randomization analysis. JAMA psychiatry. 2021;78(2):151\u201360.","journal-title":"JAMA psychiatry"},{"issue":"2-3","key":"954_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jad.2012.03.025","volume":"141","author":"W Linden","year":"2012","unstructured":"Linden W, Vodermaier A, Mackenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141(2-3):343\u201351.","journal-title":"J Affect Disord"},{"issue":"2","key":"954_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160\u201374.","journal-title":"Lancet Oncol"},{"issue":"5","key":"954_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S2215-0366(14)70313-X","volume":"1","author":"J Walker","year":"2014","unstructured":"Walker J, Hansen CH, Martin P, Symeonides S, Ramessur R, Murray G, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry. 2014;1(5):343\u201350.","journal-title":"Lancet Psychiatry"},{"issue":"1-2","key":"954_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drugalcdep.2010.05.017","volume":"112","author":"MJ Edlund","year":"2010","unstructured":"Edlund MJ, Martin BC, Fan MY, Devries A, Braden JB, Sullivan MD. Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend. 2010;112(1-2):90\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"954_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1370\/afm.1371","volume":"10","author":"A Grattan","year":"2012","unstructured":"Grattan A, Sullivan MD, Saunders KW, Campbell CI, Von Korff MR. Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. Ann Fam Med. 2012;10(4):304\u201311.","journal-title":"Ann Fam Med"},{"issue":"1","key":"954_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.genhosppsych.2013.10.003","volume":"36","author":"CQ Howe","year":"2014","unstructured":"Howe CQ, M.D. S. The missing \u2018P\u2019 in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care. Gen Hosp Psychiatry. 2014;36(1):99\u2013104.","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"954_CR15","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/AJP.0000000000000603","volume":"34","author":"MD Sullivan","year":"2018","unstructured":"Sullivan MD. Depression effects on long-term prescription opioid use, abuse, and addiction. Clin J Pain. 2018;34(9):878\u201384.","journal-title":"Clin J Pain"},{"issue":"2","key":"954_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/j.pain.0000000000000763","volume":"158","author":"J Salas","year":"2017","unstructured":"Salas J, Scherrer JF, Schneider FD, Sullivan MD, Bucholz KK, Burroughs T, et al. New-onset depression following stable, slow, and rapid rate of prescription opioid dose escalation. Pain. 2017;158(2):306\u201312.","journal-title":"Pain."},{"key":"954_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ypmed.2016.08.003","volume":"91","author":"JF Scherrer","year":"2016","unstructured":"Scherrer JF, Salas J, Sullivan MD, Schneider FD, Bucholz KK, Burroughs T, et al. The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med. 2016;91:110\u20136.","journal-title":"Prev Med"},{"key":"954_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/01.j.pain.0000460316.58110.a0","volume":"156","author":"JF Scherrer","year":"2015","unstructured":"Scherrer JF, Salas J, Lustman PJ, Burge S, Schneider FD, Investigators rRNoTR. Change in opioid dose and change in depression in a longitudinal primary care patient cohort. Pain. 2015;156:348\u201355.","journal-title":"Pain"},{"issue":"7","key":"954_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1526-4637.2010.00881.x","volume":"11","author":"J Shurman","year":"2010","unstructured":"Shurman J, Koob GF, Gutstein HB. Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med. 2010;11(7):1092\u20138.","journal-title":"Pain Med"},{"key":"954_CR20","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Koob GF. Drug addiction: hyperkatifeia\/negative reinforcement as a framework for medications development. Pharmacol Rev. 2021;73(1):163\u2013201 Comprehensive review of addiction process in context of negative reinforcement.","DOI":"10.1124\/pharmrev.120.000083"},{"issue":"19","key":"954_CR21","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1001\/archinte.166.19.2087","volume":"166","author":"MD Sullivan","year":"2006","unstructured":"Sullivan MD, Edlund MJ, Zhang L, Unutzer J, Wells KB. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med. 2006;166(19):2087\u201393.","journal-title":"Arch Intern Med"},{"issue":"2","key":"954_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/01.j.pain.0000460316.58110.a0","volume":"156","author":"JF Scherrer","year":"2015","unstructured":"Scherrer JF, Salas J, Lustman PJ, Burge S, Schneider FD. Residency Research Network of Texas I. Change in opioid dose and change in depression in a longitudinal primary care patient cohort. Pain. 2015;156(2):348\u201355.","journal-title":"Pain."},{"issue":"10","key":"954_CR23","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1080\/13548506.2018.1476723","volume":"23","author":"PM Bamonti","year":"2018","unstructured":"Bamonti PM, Moye J, Naik AD. Pain is associated with continuing depression in cancer survivors. Psychol Health Med. 2018;23(10):1182\u201395.","journal-title":"Psychol Health Med"},{"issue":"4","key":"954_CR24","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1136\/bmjspcare-2018-001533","volume":"9","author":"CC Reyes","year":"2019","unstructured":"Reyes CC, Anderson KO, Gonzalez CE, Ochs HC, Wattana M, Acharya G, et al. Depression and survival outcomes after emergency department cancer pain visits. BMJ Support Palliat Care. 2019;9(4):e36.","journal-title":"BMJ Support Palliat Care"},{"issue":"20","key":"954_CR25","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1002\/cncr.31675","volume":"124","author":"N Osazuwa-Peters","year":"2018","unstructured":"Osazuwa-Peters N, Simpson MC, Zhao L, Boakye EA, Olomukoro SI, Deshields T, et al. Suicide risk among cancer survivors: head and neck versus other cancers. Cancer. 2018;124(20):4072\u20139.","journal-title":"Cancer."},{"key":"954_CR26","doi-asserted-by":"crossref","unstructured":"Osazuwa-Peters N, Barnes JM, Okafor SI, Taylor DB, Hussaini AS, Adjei Boakye E, et al. Incidence and risk of suicide among patients with head and neck cancer in rural, urban, and metropolitan areas. JAMA Otolaryngol Head Neck Surg. 2021.","DOI":"10.1001\/jamaoto.2021.1728"},{"issue":"6","key":"954_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jpainsymman.2017.04.010","volume":"54","author":"KS Grotmol","year":"2017","unstructured":"Grotmol KS, Lie HC, Hjermstad MJ, Aass N, Currow D, Kaasa S, et al. Depression: a major contributor to poor quality of life in patients with advanced cancer. J Pain Symptom Manag. 2017;54(6):889\u201397.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"954_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/PSY.0b013e3182590904","volume":"74","author":"HL Wang","year":"2012","unstructured":"Wang HL, Kroenke K, Wu J, Tu W, Theobald D, Rawl SM. Predictors of cancer-related pain improvement over time. Psychosom Med. 2012;74(6):642\u20137.","journal-title":"Psychosom Med"},{"issue":"20","key":"954_CR29","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","volume":"163","author":"MJ Bair","year":"2003","unstructured":"Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433\u201345.","journal-title":"Arch Intern Med"},{"issue":"3","key":"954_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/cncr.29969","volume":"123","author":"LI Wagner","year":"2017","unstructured":"Wagner LI, Pugh SL, Small W Jr, Kirshner J, Sidhu K, Bury MJ, et al. Screening for depression in cancer patients receiving radiotherapy: feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. Cancer. 2017;123(3):485\u201393.","journal-title":"Cancer."},{"issue":"1","key":"954_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jpainsymman.2011.12.284","volume":"45","author":"SA Johns","year":"2013","unstructured":"Johns SA, Kroenke K, Krebs EE, Theobald DE, Wu J, Tu W. Longitudinal comparison of three depression measures in adult cancer patients. J Pain Symptom Manag. 2013;45(1):71\u201382.","journal-title":"J Pain Symptom Manag"},{"issue":"11","key":"954_CR32","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1111\/pme.12537","volume":"15","author":"K Kroenke","year":"2014","unstructured":"Kroenke K, Yu Z, Wu J, Kean J, Monahan PO. Operating characteristics of PROMIS four-item depression and anxiety scales in primary care patients with chronic pain. Pain Med. 2014;15(11):1892\u2013901.","journal-title":"Pain Med"},{"issue":"1","key":"954_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12955-021-01674-3","volume":"19","author":"K Kroenke","year":"2021","unstructured":"Kroenke K, Stump TE, Chen CX, Kean J, Damush TM, Bair MJ, et al. Responsiveness of PROMIS and Patient Health Questionnaire (PHQ) depression scales in three clinical trials. Health Qual Life Outcomes. 2021;19(1):41.","journal-title":"Health Qual Life Outcomes"},{"key":"954_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jpsychores.2004.09.006","volume":"58","author":"B Lowe","year":"2005","unstructured":"Lowe B, Kroenke K, Grafe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J Psychosom Res. 2005;58:163\u201371.","journal-title":"J Psychosom Res"},{"key":"954_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ-9 validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"954_CR36","doi-asserted-by":"publisher","first-page":"e000034","DOI":"10.1136\/bmjoq-2017-000034","volume":"7","author":"AL Holtzman","year":"2018","unstructured":"Holtzman AL, Pereira DB, Yeung AR. Implementation of depression and anxiety screening in patients undergoing radiotherapy. BMJ Open Qual. 2018;7(2):e000034.","journal-title":"BMJ Open Qual"},{"key":"954_CR37","doi-asserted-by":"crossref","unstructured":"\u2022 Li M, Kennedy EB, Byrne N, Gerin-Lajoie C, Katz MR, Keshavarz H, et al. Management of depression in patients with cancer: a clinical practice guideline. J Oncol Pract. 2016;12(8):747\u201356 Clinical guidelines on treating depression in cancer based on systematic review of RCTs and existing evidence.","DOI":"10.1200\/JOP.2016.011072"},{"issue":"8","key":"954_CR38","doi-asserted-by":"publisher","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","volume":"17","author":"RA Swarm","year":"2019","unstructured":"Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, et al. Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(8):977\u20131007.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"45","key":"954_CR39","doi-asserted-by":"publisher","first-page":"e0897","DOI":"10.1097\/MD.0000000000000897","volume":"94","author":"MF Zhang","year":"2015","unstructured":"Zhang MF, Wen YS, Liu WY, Peng LF, Wu XD, Liu QW. Effectiveness of mindfulness-based therapy for reducing anxiety and depression in patients with cancer: a meta-analysis. Medicine (Baltimore). 2015;94(45):e0897\u20130.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"954_CR40","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1007\/s00520-016-3243-x","volume":"24","author":"PA Poulin","year":"2016","unstructured":"Poulin PA, Romanow HC, Rahbari N, Small R, Smyth CE, Hatchard T, et al. The relationship between mindfulness, pain intensity, pain catastrophizing, depression, and quality of life among cancer survivors living with chronic neuropathic pain. Support Care Cancer. 2016;24(10):4167\u201375.","journal-title":"Support Care Cancer"},{"key":"954_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctrv.2017.03.012","volume":"56","author":"T Okuyama","year":"2017","unstructured":"Okuyama T, Akechi T, Mackenzie L, Furukawa TA. Psychotherapy for depression among advanced, incurable cancer patients: a systematic review and meta-analysis. Cancer Treat Rev. 2017;56:16\u201327.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"954_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10865-005-9036-1","volume":"29","author":"K Tatrow","year":"2006","unstructured":"Tatrow K, Montgomery GH. Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a meta-analysis. J Behav Med. 2006;29(1):17\u201327.","journal-title":"J Behav Med"},{"issue":"4","key":"954_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1192\/bjp.2019.207","volume":"216","author":"M Serfaty","year":"2020","unstructured":"Serfaty M, King M, Nazareth I, Moorey S, Aspden T, Mannix K, et al. Effectiveness of cognitive-behavioural therapy for depression in advanced cancer: CanTalk randomised controlled trial. Br J Psychiatry. 2020;216(4):213\u201321.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"954_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/pon.4286","volume":"26","author":"M Li","year":"2017","unstructured":"Li M, Kennedy EB, Byrne N, Gerin-Lajoie C, Katz MR, Keshavarz H, et al. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology. 2017;26(5):573\u201387.","journal-title":"Psychooncology."},{"key":"954_CR45","doi-asserted-by":"crossref","unstructured":"\u2022 Sharpe M, Walker J, Holm Hansen C, Martin P, Symeonides S, Gourley C, et al. Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial. Lancet. 2014;384(9948):1099\u2013108 Large RCT demonstrating collaborative care beneficial for depression and pain in cancer.","DOI":"10.1016\/S0140-6736(14)61231-9"},{"key":"954_CR46","doi-asserted-by":"crossref","unstructured":"\u2022 Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018;4:CD011006 Very low quality evidence for antidepressants vs. placebo in patients with cancer in systematic review.","DOI":"10.1002\/14651858.CD011006.pub3"},{"issue":"5","key":"954_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1177\/0269216310378546","volume":"25","author":"MI Bennett","year":"2011","unstructured":"Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2011;25(5):553\u20139.","journal-title":"Palliat Med"},{"key":"954_CR48","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Grassi L, Nanni MG, Rodin G, Li M, Caruso R. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol. 2018;29(1):101\u201311 Synthesis of 30 years of data recommending antidepressants for severe depression in cancer, cautions side effects and interactions.","DOI":"10.1093\/annonc\/mdx526"},{"key":"954_CR49","doi-asserted-by":"publisher","first-page":"k1415","DOI":"10.1136\/bmj.k1415","volume":"361","author":"A Pitman","year":"2018","unstructured":"Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with cancer. BMJ. 2018;361:k1415.","journal-title":"BMJ."},{"key":"954_CR50","unstructured":"Ahmed E. Antidepressants in patients with advanced cancer: when they\u2019re warranted and how to choose therapy. Oncology (Williston Park). 2019;33(2)."},{"issue":"8","key":"954_CR51","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2174\/1389450118666170317162603","volume":"19","author":"BN Andrew","year":"2018","unstructured":"Andrew BN, Guan NC, Jaafar N. The use of methylphenidate for physical and psychological symptoms in cancer patients: a review. Curr Drug Targets. 2018;19(8):877\u201387.","journal-title":"Curr Drug Targets"},{"key":"954_CR52","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jad.2021.05.119","volume":"292","author":"A Bahji","year":"2021","unstructured":"Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416\u201323.","journal-title":"J Affect Disord"},{"issue":"4","key":"954_CR53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.euroneuro.2014.01.016","volume":"24","author":"CG Ng","year":"2014","unstructured":"Ng CG, Boks MP, Roes KC, Zainal NZ, Sulaiman AH, Tan SB, et al. Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study. Eur Neuropsychopharmacol. 2014;24(4):491\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"954_CR54","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.18632\/oncotarget.13743","volume":"8","author":"W Fan","year":"2017","unstructured":"Fan W, Yang H, Sun Y, Zhang J, Li G, Zheng Y, et al. Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. Oncotarget. 2017;8(2):2356.","journal-title":"Oncotarget."},{"issue":"2","key":"954_CR55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/SPC.0000000000000262","volume":"11","author":"K Jonkman","year":"2017","unstructured":"Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain: what is the evidence? Curr Opin Support Palliat Care. 2017;11(2):88\u201392.","journal-title":"Curr Opin Support Palliat Care"},{"key":"954_CR56","first-page":"CD003351","volume":"6","author":"RF Bell","year":"2017","unstructured":"Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2017;6:CD003351.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"954_CR57","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"954_CR58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponte KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155\u201366.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"954_CR59","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamaoncol.2020.0799","volume":"6","author":"F Chino","year":"2020","unstructured":"Chino F, Kamal A, Chino J. Incidence of opioid-associated deaths in cancer survivors in the United States, 2006-2016: a population study of the opioid epidemic. JAMA Oncol. 2020;6(7):1100\u20132.","journal-title":"JAMA Oncol"},{"issue":"7","key":"954_CR60","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jamaoncol.2020.0779","volume":"6","author":"LK Vitzthum","year":"2020","unstructured":"Vitzthum LK, Riviere P, Murphy JD. Managing cancer pain during the opioid epidemic-balancing caution and compassion. JAMA Oncol. 2020;6(7):1103\u20134.","journal-title":"JAMA Oncol"},{"key":"954_CR61","unstructured":"About the WHO WMH-CIDI: World Health Organization World Mental Health Composite International Diagnostic Interview (WHO WMH-CIDI); [Available from: https:\/\/www.hcp.med.harvard.edu\/wmhcidi\/about-the-who-wmh-cidi\/."},{"issue":"26","key":"954_CR62","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1056\/NEJMp1812850","volume":"379","author":"AW Loren","year":"2018","unstructured":"Loren AW. Harder to treat than leukemia - opioid use disorder in survivors of cancer. N Engl J Med. 2018;379(26):2485\u20137.","journal-title":"N Engl J Med"},{"key":"954_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1747-597X-8-39","volume":"8","author":"P Voon","year":"2013","unstructured":"Voon P, Kerr T. \u201cNonmedical\u201d prescription opioid use in North America: a call for priority action. Subst Abuse Treat Prev Policy. 2013;8:39.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"954_CR64","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Yusufov M, Braun IM, Pirl WF. A systematic review of substance use and substance use disorders in patients with cancer. Gen Hosp Psychiatry. 2019;60:128\u201336 Systematic review revealing high prevalence of substance use disorder in cancer patients.","DOI":"10.1016\/j.genhosppsych.2019.04.016"},{"issue":"21","key":"954_CR65","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1002\/cncr.30839","volume":"123","author":"R Sutradhar","year":"2017","unstructured":"Sutradhar R, Lokku A, Barbera L. Cancer survivorship and opioid prescribing rates: a population-based matched cohort study among individuals with and without a history of cancer. Cancer. 2017;123(21):4286\u201393.","journal-title":"Cancer."},{"issue":"1","key":"954_CR66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jpainsymman.2018.10.493","volume":"57","author":"JS Merlin","year":"2019","unstructured":"Merlin JS, Patel K, Thompson N, Kapo J, Keefe F, Liebschutz J, et al. Managing chronic pain in cancer survivors prescribed long-term opioid therapy: a national survey of ambulatory palliative care providers. J Pain Symptom Manag. 2019;57(1):20\u20137.","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"954_CR67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jpainsymman.2011.03.009","volume":"43","author":"JW Childers","year":"2012","unstructured":"Childers JW, Arnold RM. \u201cI feel uncomfortable \u2018calling a patient out\u2019\u201d: educational needs of palliative medicine fellows in managing opioid misuse. J Pain Symptom Manag. 2012;43(2):253\u201360.","journal-title":"J Pain Symptom Manag"},{"key":"954_CR68","first-page":"71","volume":"7","author":"AN Carmichael","year":"2016","unstructured":"Carmichael AN, Morgan L, Del Fabbro E. Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review. Subst Abus Rehabil. 2016;7:71\u20139.","journal-title":"Subst Abus Rehabil"},{"key":"954_CR69","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ulker E, Del Fabbro E. Best practices in the management of nonmedical opioid use in patients with cancer-related pain. Oncologist. 2020;25(3):189\u201396 Narrative review and best practice recommendations for NMOU management in oncology.","DOI":"10.1634\/theoncologist.2019-0540"},{"issue":"15","key":"954_CR70","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain--United States, 2016. JAMA. 2016;315(15):1624\u201345.","journal-title":"JAMA."},{"issue":"27","key":"954_CR71","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.2016.68.5206","volume":"34","author":"JA Paice","year":"2016","unstructured":"Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325\u201345.","journal-title":"J Clin Oncol"},{"issue":"4","key":"954_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41571-018-0143-7","volume":"16","author":"J Arthur","year":"2019","unstructured":"Arthur J, Bruera E. Balancing opioid analgesia with the risk of nonmedical opioid use in patients with cancer. Nat Rev Clin Oncol. 2019;16(4):213\u201326.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"954_CR73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7326\/0003-4819-160-1-201401070-00732","volume":"160","author":"TK Nuckols","year":"2014","unstructured":"Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160(1):38\u201347.","journal-title":"Ann Intern Med"},{"issue":"16","key":"954_CR74","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1200\/JCO.2013.52.5170","volume":"32","author":"E Del Fabbro","year":"2014","unstructured":"Del Fabbro E. Assessment and management of chemical coping in patients with cancer. J Clin Oncol. 2014;32(16):1734\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"954_CR75","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40265-018-0953-z","volume":"78","author":"MP Davis","year":"2018","unstructured":"Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018;78(12):1211\u201328.","journal-title":"Drugs."},{"issue":"22","key":"954_CR76","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies\u2014tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063\u20136.","journal-title":"N Engl J Med"},{"key":"954_CR77","doi-asserted-by":"crossref","unstructured":"Schmidt-Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Buprenorphine for treating cancer pain. Cochrane Database Syst Rev 2015(3):CD009596.","DOI":"10.1002\/14651858.CD009596.pub4"},{"key":"954_CR78","first-page":"CD003971","volume":"2","author":"AB Nicholson","year":"2017","unstructured":"Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain. Cochrane Database Syst Rev. 2017;2:CD003971.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"954_CR79","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/jcsm.12352","volume":"9","author":"RH Schuchen","year":"2018","unstructured":"Schuchen RH, Mucke M, Marinova M, Kravchenko D, Hauser W, Radbruch L, et al. Systematic review and meta-analysis on non-opioid analgesics in palliative medicine. J Cachexia Sarcopenia Muscle. 2018;9(7):1235\u201354.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"954_CR80","doi-asserted-by":"publisher","first-page":"e180919","DOI":"10.1001\/jamanetworkopen.2018.0919","volume":"1","author":"I Hernandez","year":"2018","unstructured":"Hernandez I, He M, Brooks MM, Zhang Y. Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare Part D beneficiaries. JAMA Netw Open. 2018;1(2):e180919.","journal-title":"JAMA Netw Open"},{"key":"954_CR81","doi-asserted-by":"crossref","unstructured":"\u2022 Arthur J, Edwards T, Reddy S, Nguyen K, Hui D, Yennu S, et al. Outcomes of a specialized interdisciplinary approach for patients with cancer with aberrant opioid-related behavior. Oncologist. 2018;23(2):263\u201370 Interdisciplinary intervention associated with reduction inaberrants opioid related behavior in cancer patients.","DOI":"10.1634\/theoncologist.2017-0248"},{"issue":"1","key":"954_CR82","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jpainsymman.2021.01.005","volume":"62","author":"JS Amaram-Davila","year":"2021","unstructured":"Amaram-Davila JS, Arthur J, Reddy A, Bruera E. Managing nonmedical opioid use among patients with cancer pain during the COVID-19 pandemic using the CHAT model and telehealth. J Pain Symptom Manag. 2021;62(1):192\u20136.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"954_CR83","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jpainsymman.2020.08.031","volume":"60","author":"AA Case","year":"2020","unstructured":"Case AA, Walter M, Pailler M, Stevens L, Hansen E. A practical approach to nonmedical opioid use in palliative care patients with cancer: using the PARTNERS framework. J Pain Symptom Manag. 2020;60(6):1253\u20139.","journal-title":"J Pain Symptom Manag"},{"issue":"9","key":"954_CR84","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3109\/10826084.2016.1160118","volume":"51","author":"CD Darker","year":"2016","unstructured":"Darker CD, Sweeney B, Keenan E, Whiston L, Anderson R, Barry J. Screening and brief interventions for illicit drug use and alcohol use in methadone maintained opiate-dependent patients: results of a pilot cluster randomized controlled trial feasibility study. Subst Use Misuse. 2016;51(9):1104\u201315.","journal-title":"Subst Use Misuse"},{"issue":"5","key":"954_CR85","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363\u201385.","journal-title":"CA Cancer J Clin"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-00954-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-022-00954-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-00954-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:28:26Z","timestamp":1744183706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-022-00954-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["954"],"URL":"https:\/\/doi.org\/10.1007\/s11864-022-00954-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"9 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicole Bates is supported, in part, by a National Cancer Institute (NCI) funded clinical trial (NCT05012124). Jennifer K. Bello declares that she has no conflict of interest. Nosayaba Osazuwa-Peters is supported, in part, by a grant (K01DE030916) from the National Institutes of Health (NIH). Mark Sullivan is supported, in part, by a grant (R01DA043811) from the NIH; and is a board member of Physicians for Responsible Opioid Prescribing. This is an unpaid advisory position. Jeffrey F. Scherrer is supported, in part, by a grant (R01DA043811) from the NIH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}